State‐of‐the‐art Nrf2 Inhibitors: Therapeutic Opportunities in Non‐cancer Diseases DOI

Emil G. Ayala‐Cosme,

Deborah J. Yang,

Kyara Vences

и другие.

ChemMedChem, Год журнала: 2024, Номер unknown

Опубликована: Июль 31, 2024

Abstract Nuclear factor erythroid 2‐related (Nrf2) is a cytoprotective transcription that induces the of genes responsible for cell's response to oxidative stress. While Nrf2 activation has led development clinically relevant therapeutics, oncogenic role in proliferation cancer cells underscored complex nature and necessity inhibitors. Although application inhibitors appears limited as anticancer agents, recent studies have begun pinpoint impairment autophagy diseases cellular marker shifts from protective deleterious state. Therefore, cytoplasmic accumulation can lead lipid hydroperoxides and, ultimately, ferroptosis. However, some aimed at elucidating non‐cancer yielded conflicting results, attributed differences approaches used inhibit or activate Nrf2, well variations vitro and/or vivo disease models. Overall, these results highlight deeper evaluation Nrf2′s diseases, especially chronic diseases. In this review, we discuss where inhibition holds potential beneficial therapeutic effects summarize recently reported exploiting medicinal chemistry suitable targeting factors like Nrf2.

Язык: Английский

Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma DOI
Yulong Ma,

Liming Cong,

Wenxiang Shen

и другие.

Cell Biochemistry and Function, Год журнала: 2024, Номер 42(4)

Опубликована: Июнь 1, 2024

Currently, challenges such as chemotherapy resistance, resulting from preoperative and postoperative chemotherapy, recurrence, poor bone regeneration quality, are becoming increasingly prominent in osteosarcoma (OS) treatment. There is an urgent need to find more effective ways address these issues. Ferroptosis a novel form of iron-dependent programmed cell death, distinct other forms death. In this paper, we summarize how, through the three major defense systems ferroptosis, not only can substances traditional Chinese medicine, antitumor drugs, nano-drug carriers induce ferroptosis OS cells, but they also be combined with immunotherapy, differentiation therapy, treatment modalities significantly enhance sensitivity inhibit tumor growth. Thus, holds great potential treating OS, offering choices possibilities for future clinical interventions.

Язык: Английский

Процитировано

2
State‐of‐the‐art Nrf2 Inhibitors: Therapeutic Opportunities in Non‐cancer Diseases DOI

Emil G. Ayala‐Cosme,

Deborah J. Yang,

Kyara Vences

и другие.

ChemMedChem, Год журнала: 2024, Номер unknown

Опубликована: Июль 31, 2024

Abstract Nuclear factor erythroid 2‐related (Nrf2) is a cytoprotective transcription that induces the of genes responsible for cell's response to oxidative stress. While Nrf2 activation has led development clinically relevant therapeutics, oncogenic role in proliferation cancer cells underscored complex nature and necessity inhibitors. Although application inhibitors appears limited as anticancer agents, recent studies have begun pinpoint impairment autophagy diseases cellular marker shifts from protective deleterious state. Therefore, cytoplasmic accumulation can lead lipid hydroperoxides and, ultimately, ferroptosis. However, some aimed at elucidating non‐cancer yielded conflicting results, attributed differences approaches used inhibit or activate Nrf2, well variations vitro and/or vivo disease models. Overall, these results highlight deeper evaluation Nrf2′s diseases, especially chronic diseases. In this review, we discuss where inhibition holds potential beneficial therapeutic effects summarize recently reported exploiting medicinal chemistry suitable targeting factors like Nrf2.

Язык: Английский

Процитировано

0